QuickView for YDL103C;jsessionid=15F15BB478DC6C77651BC16CE76A6F8A;jsessionid=FA09DD4A5D65571BA1AD979499E356E2;jsessionid=5DB5107377C50D220B2B02849FAC3A0E;jsessionid=2766B9A4379564671E9BCB65AB596CAF;jsessionid=A06FF884E94C89B37D11661C0B1FCC3D;jsessionid=C9D3C0005C04116F11F9144A1B30FB1B;jsessionid=FC7A42C6408FDA2AD53FE68669585523;jsessionid=19609E1F79F04D1A5C9B04929DFC6D9E;jsessionid=088116F3CB3A1164419B03050D43C471;jsessionid=6C2396FD087DA79C594B194FEA1B1238 (gene)

1. Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm.
2. Clinical Evaluation of Cystic Renal Masses With Bosniak Classification by Contrast-Enhanced Ultrasou…
3. Feasibility of Surveillance for Mucinous Cystic Neoplasm of the Pancreas: A Multi-Institutional Retr…
4. Clinicopathological and genetic characteristics of congenital cystic adenomatoid malformation of lun…
5. The added value of contrast-enhanced ultrasound in evaluation of indeterminate small solid renal mas…

There were no clinical trials for YDL103C;jsessionid=15F15BB478DC6C77651BC16CE76A6F8A;jsessionid=FA09DD4A5D65571BA1AD979499E356E2;jsessionid=5DB5107377C50D220B2B02849FAC3A0E;jsessionid=2766B9A4379564671E9BCB65AB596CAF;jsessionid=A06FF884E94C89B37D11661C0B1FCC3D;jsessionid=C9D3C0005C04116F11F9144A1B30FB1B;jsessionid=FC7A42C6408FDA2AD53FE68669585523;jsessionid=19609E1F79F04D1A5C9B04929DFC6D9E;jsessionid=088116F3CB3A1164419B03050D43C471;jsessionid=6C2396FD087DA79C594B194FEA1B1238